Hong Kong SMA Patients Urge Government to Subsidize Adult Injection Therapy
Spinal muscular atrophy (SMA) patients in Hong Kong are calling on the government to expand subsidized medication options for adults, specifically requesting public funding for injection therapy. While subsidies for oral medicine were extended to patients aged 25 and older in early 2026, adult patients currently lack financial support for injectable treatments, which many argue are medically necessary for their specific conditions. Lui Man-lam, president of the Hong Kong Neuro-Muscular Disease Association, emphasized at a recent press conference that the advocacy for equal subsidies is driven by individual medical needs rather than preference. SMA is a hereditary neuromuscular disease causing progressive muscle weakness and impaired movement. Although Hong Kong began subsidizing injection treatments for children under 18 in 2018, adults have been left without comparable support. Patients report that their conditions deteriorated after growing up without affordable care. The association seeks to ensure that all patients, regardless of age, have access to effective treatments to improve their quality of life, highlighting a gap in the current healthcare subsidy framework provided by the Community Care Fund.
Wire timeline
Hong Kong SMA Patients Urge Government to Subsidize Adult Injection Therapy
Spinal muscular atrophy (SMA) patients in Hong Kong are calling on the government to expand subsidized medication options for adults, specifically requesting public funding for injection therapy. While subsidies for oral medicine were extended to patients aged 25 and older in early 2026, adult patients currently lack financial support for injectable treatments, which many argue are medically necessary for their specific conditions. Lui Man-lam, president of the Hong Kong Neuro-Muscular Disease Association, emphasized at a recent press conference that the advocacy for equal subsidies is driven by individual medical needs rather than preference. SMA is a hereditary neuromuscular disease causing progressive muscle weakness and impaired movement. Although Hong Kong began subsidizing injection treatments for children under 18 in 2018, adults have been left without comparable support. Patients report that their conditions deteriorated after growing up without affordable care. The association seeks to ensure that all patients, regardless of age, have access to effective treatments to improve their quality of life, highlighting a gap in the current healthcare subsidy framework provided by the Community Care Fund.
News - South China Morning Post